Table 3. Distribution and prevalence of individual HPV genotypes according to cervical cytology findings.
| Cervical cytology findings | Total (N=18,815) | P value | HSIL:WNL ratio | |||||
|---|---|---|---|---|---|---|---|---|
| WNL (N=15,426) |
ASCUS/AGUS (N=3,041) |
LSIL (N=178) |
ASC-H (N=76) |
HSIL* (N=94) |
||||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
| Any HPV | 3,370 (21.9) | 1,533 (50.4) | 160 (89.9) | 71 (93.4) | 93 (98.9) | 5,227 (27.8) | < 0.001 | |
| HR-HPV | 2,519 (16.3) | 1,358 (44.7) | 143 (80.3) | 70 (92.1) | 93 (98.9) | 4,183 (22.2) | < 0.001 | |
| 16 | 191 (1.2) | 145 (4.8) | 8 (4.5) | 17 (22.4) | 17 (18.1) | 378 (2) | < 0.001 | 2.41 |
| 18 | 111 (0.7) | 65 (2.1) | 4 (2.3) | 1 (1.3) | 4 (4.3) | 185 (1) | < 0.001 | 0.98 |
| 31 | 94 (0.6) | 70 (2.3) | 6 (3.4) | 11 (14.5) | 8 (8.5) | 189 (1) | < 0.001 | 2.31 |
| 33 | 77 (0.5) | 58 (1.9) | 7 (3.9) | 5 (6.6) | 16 (17) | 163 (0.9) | < 0.001 | 5.63 |
| 35 | 126 (0.8) | 82 (2.7) | 6 (3.4) | 9 (11.8) | 6 (6.4) | 229 (1.2) | < 0.001 | 1.29 |
| 39 | 165 (1.1) | 73 (2.4) | 9 (5.1) | 1 (1.3) | 3 (3.2) | 251 (1.3) | < 0.001 | 0.49 |
| 45 | 39 (0.3) | 23 (0.8) | 1 (0.6) | - | 3 (3.2) | 66 (0.4) | < 0.001 | < 0.001 |
| 51 | 174 (1.1) | 123 (4) | 23 (12.9) | 5 (6.6) | 8 (8.5) | 333 (1.8) | < 0.001 | 1.25 |
| 52 | 296 (1.9) | 256 (8.4) | 19 (10.7) | 20 (26.3) | 12 (12.8) | 603 (3.2) | < 0.001 | 1.10 |
| 56 | 200 (1.3) | 122 (4) | 23 (12.9) | 7 (9.2) | 3 (3.2) | 355 (1.9) | < 0.001 | 0.41 |
| 58 | 241 (1.6) | 212 (7) | 18 (10.1) | 10 (13.2) | 21 (22.3) | 502 (2.7) | < 0.001 | 2.36 |
| 59 | 93 (0.6) | 42 (1.4) | 5 (2.8) | - | 2 (2.1) | 142 (0.8) | < 0.001 | < 0.001 |
| 68 | 383 (2.5) | 159 (5.2) | 14 (7.9) | 4 (5.3) | 3 (3.2) | 563 (3) | < 0.001 | 0.21 |
| 66 | 192 (1.2) | 93 (3.1) | 19 (10.7) | 3 (3.9) | 3 (3.2) | 310 (1.7) | < 0.001 | 0.42 |
| 26 | 7 (0.1) | 5 (0.2) | 1 (0.6) | - | - | 13 (0.1) | 0.043 | |
| 53 | 424 (2.8) | 241 (7.9) | 34 (19.1) | 8 (10.5) | 8 (8.5) | 715 (3.8) | < 0.001 | 0.51 |
| 69 | 30 (0.2) | 24 (0.8) | 7 (3.9) | - | 1 (1.1) | 62 (0.3) | < 0.001 | 0.90 |
| 70 | 373 (2.4) | 202 (6.6) | 14 (7.9) | 6 (7.9) | 7 (7.4) | 602 (3.2) | < 0.001 | 0.51 |
| 73 | 22 (0.1) | 15 (0.5) | 2 (1.1) | - | - | 39 (0.2) | 0.004 | |
| 82 | 61 (0.4) | 36 (1.2) | 3 (1.7) | - | 2 (2.1) | 102 (0.5) | < 0.001 | 0.89 |
| LR-HPV | 1,495 (9.7) | 563 (18.5) | 60 (33.7) | 13 (17.1) | 19 (20.2) | 2,150 (11.4) | < 0.001 | |
| Multiple | 1,132 (33.6) | 715 (46.6) | 87 (54.4) | 26 (34.2) | 34 (36.2) | 1,994 (38.1) | < 0.001 | |
P value for trend of HPV infection prevalence rate according to cervical cytology findings was determined by using the Cochran-Armitage trend test.
*HSIL included two cancer cases (squamous cell carcinoma and adenocarcinoma).
Abbreviations: WNL, well normal limit; ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells without excluding HSIL; HSIL, high-grade intraepithelial lesion; HPV, human papillomavirus; HR-HPV, high-risk human papillomavirus; LR-HPV, low-risk human papillomavirus.